Bristol-Myers Squibb Company (BMY)
$59.17
-1.85 (-2.94%)Delayed quote.
Price history
Daily close- Start
- $45.94
- Latest close
- $58.34
- Period change
- +26.99%
- Period low
- $45.94
- Period high
- $68.09
Key metrics
- Market cap
- $124.85B
- Volume
- 4.06M
- Average volume
- 11.29M
- 52-week range
- $45.52 – $68.64
- Beta
- 0.23
- Last dividend
- $2.52
- EPS (TTM)
- $4.52
- P/E ratio
- 13.09
- Revenue (TTM)
- $50.03B
- Net income (TTM)
- $9.24B
- Total assets
- $88.77B
- Total debt
- $44.81B
- Cash and equivalents
- $9.57B
Key financials (trailing twelve months).
Company profile
Bristol-Myers Squibb Company operates as a global biopharmaceutical entity, actively involved in the research, development, licensing, production, and worldwide commercialization of its medicinal portfolio. The company's therapeutic areas span hematology, oncology, cardiovascular health, immunology, fibrotic conditions, neuroscience, and infectious diseases like COVID-19. Its significant pharmaceutical offerings include Revlimid, an oral immunomodulatory agent for multiple myeloma, and Eliquis, an oral anticoagulant crucial for reducing stroke risk and systemic embolism in non-valvular atrial fibrillation, as well as treating deep vein thrombosis and pulmonary embolism. The portfolio also features Opdivo, utilized across various anti-cancer indications; Pomalyst/Imnovid, prescribed for multiple myeloma patients; and Orencia, targeting active rheumatoid arthritis and psoriatic arthritis in adults. Other key therapies are Sprycel, employed in the management of Philadelphia chromosome-positive chronic myeloid leukemia; Yervoy, indicated for patients with unresectable or metastatic melanoma; and Abraxane, a protein-bound chemotherapy formulation. Furthermore, Bristol-Myers Squibb offers Reblozyl, addressing anemia in adult patients with beta thalassemia; Empliciti, another treatment option for multiple myeloma; and Zeposia, designed to treat relapsing forms of multiple sclerosis. Revolutionary treatments like Breyanzi, a CD19-directed genetically modified autologous T cell immunotherapy for adult patients battling relapsed or refractory large B-cell lymphoma, are also part of its lineup. Completing its product range are Inrebic, an oral kinase inhibitor specifically for adult myelofibrosis, and Onureg, used in the treatment of adult patients with acute myeloid leukemia (AML). Bristol-Myers Squibb distributes its pharmaceutical products through a diverse network encompassing wholesalers, distributors, pharmacies, retail outlets, hospitals, clinics, and governmental organizations. Founded in 1887 and formerly known as Bristol-Myers Company, the firm maintains its headquarters in New York, New York.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- Exchange
- NYSE
- CEO
- Christopher Boerner
- Employees
- 32,500
- Headquarters
- Princeton, NJ, US
- IPO date
- 1972-06-01
- Website
- https://www.bms.com
Financial statements
Annual, last 3 fiscal years. Most recent period first. Reported in USD.
| Metric | FY2025Dec 31, 2025 | FY2024Dec 31, 2024 | FY2023Dec 31, 2023 |
|---|---|---|---|
| Revenue | $48.20B | $48.30B | $45.01B |
| Gross profit | $34.26B | $34.33B | $34.31B |
| Operating income | $13.72B | $5.89B | $8.20B |
| EBITDA | $15.23B | $3.17B | $19.37B |
| Net income | $7.05B | -$8.95B | $8.03B |
| Diluted EPS | $3.45 | -$4.41 | $3.86 |
| Metric | FY2025Dec 31, 2025 | FY2024Dec 31, 2024 | FY2023Dec 31, 2023 |
|---|---|---|---|
| Cash and equivalents | $10.21B | $10.35B | $11.46B |
| Total assets | $90.04B | $92.60B | $95.16B |
| Total liabilities | $71.53B | $76.22B | $65.67B |
| Total debt | $47.14B | $51.20B | $41.46B |
| Shareholders’ equity | $18.47B | $16.34B | $29.43B |
| Metric | FY2025Dec 31, 2025 | FY2024Dec 31, 2024 | FY2023Dec 31, 2023 |
|---|---|---|---|
| Operating cash flow | $14.16B | $15.19B | $13.86B |
| Capital expenditure | -$1.31B | -$1.25B | -$1.21B |
| Free cash flow | $12.85B | $13.94B | $12.65B |
Quarterly, last 6 quarters. Most recent period first. Reported in USD.
| Metric | Q3 2026Sep 30, 2026 | Q2 2026Jun 30, 2026 | Q1 2026Mar 31, 2026 | Q4 2025Dec 31, 2025 | Q3 2025Sep 30, 2025 | Q2 2025Jun 30, 2025 |
|---|---|---|---|---|---|---|
| Revenue | $13.07B | $12.97B | $11.49B | $12.50B | $12.22B | $12.27B |
| Gross profit | $8.92B | $9.25B | $8.07B | $8.41B | $8.79B | $8.90B |
| Operating income | $2.84B | $4.03B | $3.37B | $2.81B | $3.64B | $3.77B |
| EBITDA | $2.94B | $5.09B | $4.25B | $2.88B | $4.61B | $3.27B |
| Net income | $2.16B | $3.32B | $2.68B | $1.09B | $2.20B | $1.31B |
| Diluted EPS | $1.05 | $1.62 | $1.31 | $0.53 | $1.08 | $0.64 |
| Metric | Q3 2026Sep 30, 2026 | Q2 2026Jun 30, 2026 | Q1 2026Mar 31, 2026 | Q4 2025Dec 31, 2025 | Q3 2025Sep 30, 2025 | Q2 2025Jun 30, 2025 |
|---|---|---|---|---|---|---|
| Cash and equivalents | $9.57B | $8.72B | $9.57B | $10.21B | $15.73B | $12.60B |
| Total assets | $88.77B | $87.63B | $86.48B | $90.04B | $96.89B | $94.68B |
| Total liabilities | $65.37B | $65.31B | $66.37B | $71.53B | $78.29B | $77.19B |
| Total debt | $44.81B | $43.12B | $46.43B | $47.14B | $51.04B | $50.93B |
| Shareholders’ equity | $23.40B | $22.32B | $20.07B | $18.47B | $18.55B | $17.43B |
| Metric | Q3 2026Sep 30, 2026 | Q2 2026Jun 30, 2026 | Q1 2026Mar 31, 2026 | Q4 2025Dec 31, 2025 | Q3 2025Sep 30, 2025 | Q2 2025Jun 30, 2025 |
|---|---|---|---|---|---|---|
| Operating cash flow | $4.18B | $3.39B | $1.10B | $1.97B | $6.31B | $3.92B |
| Capital expenditure | -$344.00M | -$305.00M | -$347.00M | -$370.00M | -$320.00M | -$361.00M |
| Free cash flow | $3.84B | $3.09B | $757.00M | $1.60B | $5.99B | $3.56B |